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Benzene, an important industrial solvent, is also present in unleaded gasoline and cigarette
smoke. The hematotoxic effects of benzene in humans are well documented and include aplastic
anemia, pancytopenia, and acute myelogenous leukemia. However, the risks of leukemia at low
exposure concentrations have not been established. A combination of metabolites (hydroquinone
and phenol, for example) may be necessary to duplicate the hematotoxic effect of benzene,
perhaps due in part to the synergistic effect of phenol on myeloperoxidase-mediated oxidation of
hydroquinone to the reactive metabolite benzoquinone. Because benzene and its hydroxylated
metabolites (phenol, hydroquinone, and catechol) are substrates for the same cytochrome P450
enzymes, competitive interactions among the metabolites are possible. In vivo data on metabolite
formation by mice exposed to various benzene concentrations are consistent with competitive
inhibition of phenol oxidation by benzene. In vitro studies of the metabolic oxidation of benzene,
phenol, and hydroquinone are consistent with the mechanism of competitive interaction among
the metabolites. The dosimetry of benzene and its metabolites in the target tissue, bone marrow,
depends on the balance of activation processes such as enzymatic oxidation and deactivation
processes such as conjugation and excretion. Phenol, the primary benzene metabolite, can
undergo both oxidation and conjugation. Thus the potential exists for competition among various
enzymes for phenol. Zonal localization of phase and phase 11 enzymes in various regions of the
liver acinus also impacts this competition. Biologically based dosimetry models that incorporate
the important determinants of benzene flux, including interactions with other chemicals, will
enable prediction of target tissue doses of benzene and metabolites at low exposure
concentrations relevant for humans. Environ Health Perspect 104(Suppl 6):1399-1404 (1996)
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Introduction
Benzene is a ubiquitous industrial and following repeated exposure to high con-
environmental pollutant (1). It is present centrations of benzene (3,4). Benzene is
in automobile emissions, both evaporative also carcinogenic in animals (5,6).
and combustive, has been detected in Several studies have suggested that
cigarette smoke (2), and is commonly used metabolism is a key step in the develop-
as an industrial solvent in the workplace. ment ofhematotoxicity (7-9). One current
Benzene is hematotoxic and carcinogenic at hypothesis suggests that several metabolic
high concentrations. Epidemiologic studies steps are required to produce the toxic
have shown that people develop blood dis- metabolite (10). Following absorption in
orders such as pancytopenia, aplastic the blood and translocation to the liver,
anemia, and acute myelogenous leukemia benzene is metabolized by cytochrome
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P450 (CYP) 2E1 to its major metabolite,
phenol. Phenol can be further oxidized,
most likely by the same CYP isozyme, to
the polyhydroxylated metabolite, hydro-
quinone (11,12). Both phenol and hydro-
quinone are substrates for phase II enzymes
such as sulfotransferases and glucuronyl-
transferases (13). Phenol and hydroquinone
can also partition into blood and distribute
to other tissues, including bone marrow. In
bone marrow, the myeloperoxidase-depen-
dent metabolism ofhydroquinone to the
reactive metabolite 1,4-benzoquinone is
stimulated by the presence ofphenol (8).
1,4-Benzoquinone is myelotoxic and clasto-
genic (10,14) and may be responsible for
the toxic effects ofbenzene.
The multiple metabolic pathways for
benzene provide opportunities for interac-
tions that modulate benzene metabolism.
Specific examples ofthese interactions and
the net effect on the formation ofbenzene
metabolites and resulting hematotoxicity or
genotoxicity are discussed below.
Competitive Interactions
between Benzene and Phenol
Studies in laboratory animals exposed to
benzene by inhalation or oral administra-
tion have demonstrated that the metabo-
lism of benzene is dose dependent (15).
The metabolites of benzene are quantita-
tively excreted in urine, and the profile of
urinary metabolites after benzene exposure
can serve as an effective indicator of flux
through the various metabolic pathways
because little benzene is metabolized to CO2
(16). In mice exposed to benzene by inhala-
tion, the percentage ofthe total amount of
urinary metabolites eliminated as hydro-
quinone glucuronide and hydroquinone
sulfate decreased as the benzene exposure
concentration increased from 5 to 600
ppm (17). In contrast, the glucuronide,
sulfate, and glutathione conjugates ofphe-
nol represent an increasing percentage of
the total metabolites eliminated in urine
with increasing exposure concentration.
This dose-dependent metabolism of
benzene can be explained in part by the
interaction between benzene and its major
metabolite, phenol. For example, both
benzene and phenol are substrates for
CYP2E1 (11,12) and have similar affinities.
Because the concentrations of phenol in
liver are much less than those of benzene,
benzene can be an effective inhibitor of
phenol oxidation, thereby decreasing the
formation of hydroquinone conjugates.
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Blood concentrations of benzene in male
F344 rats are 10-fold higher than those of
phenol after a 6-hr inhalation exposure to
500 ppm, suggesting that there is sufficient
benzene in the liver to inhibit phenol oxi-
dation (18). With oxidation inhibited by
benzene, phenol can be removed by enzy-
matic conjugation with glucuronic acid or
phosphoadenosine-phosphosulfate. This
mechanism of competitive inhibition is
consistent with the decrease in total hydro-
quinone conjugates and the increase in
phenol conjugates found with exposure to
increasing doses of benzene (17). The
decrease in hydroquinone glucuronide for-
mation is especially apparent between 50
and 600 ppm, when metabolism shifts
from apparent first-order to saturating. In
fact, more total hydroquinone glucuronide
is formed at 50 ppm than at 600 ppm (17).
This unusual dose-response pattern is not
explained by simple saturable or Michaelis-
Menten kinetics but has been seen with
other parent chemical/metabolite pairs that
are substrates for the same enzyme (19).
Schlosser et al. (11) investigated the
metabolism of benzene and phenol by
mouse and rat liver microsome prepara-
tions in vitro. Using microsomal incuba-
tions, the conversion of benzene to its
oxidation products can be studied apart
from other detoxifying processes in a con-
trolled and detailed manner. A quantitative
simulation model describing the in vitro
metabolism of benzene incorporated these
reaction sequences: benzene-4phenol and
phenol-ocatechol---trihydroxy-benzene or
phenol-hydroquinone->trihydroxyben-
zene. In the model, all reaction steps were
assumed to be catalyzed by the same
enzyme, CYP2E1. Benzene, phenol, hydro-
quinone, and catechol in solution were all
assumed to compete through reversible
binding for the same reaction site on CYP.
The simulation model accurately described
both benzene and phenol kinetic data sup-
porting competition for a single enzyme.
Figure 1 illustrates the formation ofhydro-
quinone from phenol and the formation of
hydroquinone from benzene using the in
vitro simulation model for mice. The same
rate constants and model structure were
used to describe both data sets. The charac-
teristic lag time for the formation ofhydro-
quinone when starting with benzene as a
substrate is due to the fact that phenol is an
intermediate in the oxidation ofbenzene to
hydroquinone. In particular, the simulation
model suggests that the observed inhibitory
effect of benzene on phenol metabolism
and of phenol on benzene metabolism
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Figure 1. Data points and error bars (mean ± SD) are the results of experiments with mouse liver microsomes, and
lines are model predictions for disappearance of substrate and formation of metabolites. Circles, squares and dia-
monds represent benzene, phenol, and hydroquinone, respectively. Solid lines are numerical simulations for the
model equations using parameter values and model structure previously published by Schlosser et al. (11). Figure
updated from Medinsky(38), with permission.
occurs through competition for a common
reaction site that can also bind catechol
and hydroquinone.
Heterogeneous Distribution
of Hepatic Enzymes
Phenol plays a pivotal role in the metabolism
of benzene because it is capable of under-
going oxidation to the polyhydroxylated
metabolite hydroquinone and also conju-
gation via sulfo or glucuronyl transferases.
Kenyon et al. (20) investigated the metab-
olism ofphenol because of its importance
as an oxidized metabolite of benzene and
because of the distinct differences in both
carcinogenic and genotoxic responses
between benzene and phenol in mice. For
example, although benzene is carcinogenic
at multiple sites in mice after both oral and
inhalation exposure (5), no increased inci-
dence of tumors was found in a 2-year
National Cancer Institute bioassay in which
male and female B6C3F1 mice were exposed
to phenol in drinking water at levels ofup
to 5000 ppm (21). Benzene has been
consistently found to induce micronuclei in
mouse bone marrow cells (22-24). In
contrast, both weakly positive and negative
results have been reported for micronuclei
induction in mouse bone marrow cells by
phenol after ip and oral administration.
Hydroquinone, the oxidized metabolite of
phenol, induces sister chromatid exchanges
in vitro in human lymphocytes (14) and in
vivo in mouse bone marrow cells (25,26).
Insights into a possible metabolism-
based explanation for the high potency of
benzene as a carcinogen and the lack of
genotoxic and carcinogenic effects ofphenol
can be gained bycomparing urinary metabo-
lite profiles after comparable oral doses of
benzene and phenol. This comparison is pre-
sented in Table 1 using data for urinary
excretion ofmetabolites following oral gav-
age ofphenol in male B6C3F1 mice (20)
and similar data following oral gavage with
benzene (15). Differences in the excretion of
hydroquinone glucuronide are marked,
particularly at the lower dose (approximately
1 mg/kg). Excretion ofhydroquinone glu-
curonide in urine was 6-fold and 2-fold
greater after benzene exposure compared
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Table 1. Comparison of percentage of urinary metabolites excreted as phenol sulfate, phenol glucuronide, and
hydroquinone glucuronide after gavage administration of phenol or benzene in male B6C3F1 mice.
Percentage oftotal metabolites in urine, mean±SE
Chemical Dose, Phenol Phenol Hydroquinone
administered mg/kg sulfate glucuronide glucuronide
Benzenea 1 26 ± 0.3 4.2 ± 0.3 43 ± 0.8
Phenolb 1.4 56 ± 0.9 39 ± 1.1 7.2 ± 0.4
Benzenea 10 32 ± 0.8 5.9 ± 0.3 36 ± 0.4
Phenolb 9.4 57 ± 7.7 26± 6.4 15 ± 1.6
aUrinary metabolite data after benzene exposure are from Sabourin et al. (15). bUrinary metabolite data following
phenol exposure are from Kenyon et al. (20).
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Figure 2. Hypothesized major relative hepatic zonal differences in metabolism of IA) benzene compared to(B) phenol
after gavage administration during an initial pass through the liver. (0) Benzene, (U) phenol, (*) hydroquinone.
PV, portal vein; THV, terminal hepatic venule. Benzene and phenol absorbed from the gastrointestinal (GI) tract are
sequentially available for metabolism in the GI mucosa and periportal (zone 1) and pericentral (zone 3) regions of
the liver. The overall capacity of GI mucosal metabolism is low relative to that ofthe liver. Periportal localization of
the enzymes (sulfotransferases) responsible for phenol sulfation suggests that less free phenol reached the peri-
central hepatocytes, whereas higher levels of CYP2E1 activity are localized. The necessity for oxidation of benzene
before conjugation suggests that more benzene will reach the pericentral hepatocytes for oxidation to phenol and
hydroquinone. Figure adapted from Kenyon et al. (20), with permission.
with phenol at doses ofapproximately 1 and
10 mg/kg, respectively. This difference is of
interest because hydroquinone is a potent
inducer of micronuclei and chromosome
aberrations. Thus, the greater production of
hydroquinone after benzene administration
compared with phenol administration,
together with production of other toxic
metabolites unique to benzene such as
muconaldehyde, provides a possible meta-
bolic basis for the carcinogenic and geno-
toxic effects observed with benzene but not
with phenol.
The differences in the urinary metabo-
lite profiles ofphenol compared with ben-
zene after oral administration are explicable
in terms ofquantitative differences in the
zonal distribution ofmetabolizing enzymes
within the liver acinus, as illustrated in
Figure 2. Phenol absorbed from the gut
lumen has a relatively greater opportunity for
conjugation than for oxidation. Conjugation
can occur initially in the gastrointestinal
mucosal cells (sulfation and glucuronidation)
and subsequently in periportal hepatocytes
ofzone 1 (sulfation) after phenol is absorbed
into the portal circulation. Preferential con-
jugation ofphenol is a consequence of a
greater abundance ofconjugating enzymes
compared with oxidative enzymes in the
periportal area, where phenol is distributed
when initially absorbed (27,28). The net
effect of this hypothetical scenario is that
relatively little phenol reaches hepatic zone
3 where oxidative enzyme activity is great-
est. Therefore, less hydroquinone is pro-
duced. In contrast to phenol, benzene
requires oxidation by CYP2E1 (12) before
it can be a substrate for conjugation, and
CYP2E1 activity is much greater in the
pericentral hepatocytes of zone 3 (29).
Thus, metabolism ofbenzene is minimal in
periportal and midzonal hepatocytes before
reaching hepatocytes in zone 3, where oxi-
dation and glucuronidation capacities are
greater (27,28). Consequently, administra-
tion ofbenzene may result in the delivery
of more free phenol to zone 3 oxidative
enzymes than does administration of
phenol itself.
The implications ofthese hypothetical
scenarios are reflected in urinary metabolite
profiles represented in Table 1 (20). Phenol
sulfate excretion is approximately 2-fold
higher and phenol glucuronide excretion
approximately 4- to 9-fold higher after
phenol compared with benzene, whereas
oxidation products such as hydroquinone
are higher after benzene exposure. The
results ofthese studies suggest that first-pass
intestinal conjugation ofphenol in combi-
nation with zonal localization ofhepatic
enzymes contributes to the greater produc-
tion ofhydroquinone after oral administra-
tion of benzene compared with oral
administration ofphenol.
The concept that the fate ofa metabo-
lite derived from a precursor differs from
that of a preformed metabolite is not new
but was proposed by Pang and Gillette (30)
for drugs. The kinetics of a drug and its
metabolite can differ due to differences in
diffusional barriers between the drug and
hepatocytes, the rate oftransport ofthe drug
between hepatocytes, and the distribution of
drug-metabolizing enzyme systems within
the liver parenchyma (31). Using the drug-
metabolite pair phenacetin and aceta-
minophen, Pang and colleagues observed
differences in clearance of the chemicals
from an isolated perfused liver depending
on whether perfusion was conducted in a
normal (portal to centrilobular) or retro-
grade (centrilobular to portal) direction
(28,30,31). They attributed these differ-
ences to localization ofP450 O-demethyla-
tion enzymes and sulfation enzymes in
different zones of the liver. Pang and col-
leagues suggested that existing models of
well-stirred livers were oversimplifications
and could only be used in limiting cases
when the distribution of enzymes was
viewed as operationally uniform.
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Using a combination of both experi-
mental and mathematical modeling
approaches, Pang et al. determined that
substrate concentration at any point is
influenced by preceding events during the
metabolic processing of a substrate along
the length of the liver sinusoid. Enzyme
systems such as sulfation, when present
upstream along the sinusoidal flow path,
modify residual substrate available for meta-
bolic processes such as oxidation within
downstream hepatocytes. In the case of
benzene and phenol, the residual phenol
available for oxidation in the centrilobular
region may be low when phenol is admin-
istered directly because most ofit is conju-
gated upstream of this region. In contrast,
when benzene is administered, the phenol
is produced in the centrilobular region and
thus is more available for subsequent oxi-
dation to hydroquinone.
Smith et al. hypothesized that 1,4-benzo-
quinone is responsible for benzene-induced
hematotoxicity (10). 1,4-Benzoquinone is
formed from the myeloperoxidase-mediated
oxidation ofhydroquinone in the bone mar-
row. The net effect ofheterogeneous distrib-
ution of enzymes in the liver and the
resulting sequential oxidation of benzene
and conjugation ofphenol is higher blood
levels ofhydroquinone after benzene admin-
istration compared with phenol administra-
tion and more hydroquinone in bone
marrow available for oxidation to 1,4-ben-
zoquinone. Localization ofenzymes in the
liver provides explanations for differences
both in observed toxicity and in in vitro
metabolism ofbenzene and phenol. Thus,
both the location and quantities ofbenzene-
metabolizing enzymes must be incorporated
into physiological models to predict risks for
humans exposed to benzene.
The role of 1,4-benzoquinone in
benzene-induced toxicity is brought into
question bystudies ofMcDonald et al., who
observed high background concentrations of
1,4-benzoquinone adducts in globin isolated
from human blood samples and in globin
and bone marrow proteins from mice and
rats (32-34). Additionally, the adducts in
rodents exposed to benzene by gavage were
only a small fraction ofthe steady-state 1,4-
benzoquinone adduct levels. McDonald and
coworkers attributed the source of the
adducts to endogenous and dietary sources
ofphenol and hydroquinone. The fact that
benzene exposure does not add significantly
to the endogenous levels of these adducts
suggests that these adducts and, by implica-
tion, 1,4-benzoquinone, do not play a role
in benzene-induced toxicity. However, it
must be recognized that background adduct
levels result from long-term exposure to
quinols, whereas the benzene-derived
adducts observed in these studies were
formed over a much shorter time. Thus, the
rate of adduct formation from benzene-
derived hydroquinone may greatly exceed
the rate offormation from other sources. It
may be the rate ofadduct formation that is a
true measure ofrisk. These results also point
to the need for incorporating all sources of
quinols (diet, cigarette smoking, and endoge-
nous production) into a risk assessment for
benzene if a quinol-related compound is
used as the ultimate dosimeter.
Individual Variability
in Human Metabolism
of Benzene
The role ofCYP2E1 in benzene metabolism
was explored by Seaton et al., who com-
pared biotransformation by liver samples
from 10 humans as well as from mice and
rats (Figure 3) (35). Benzene metabolism
correlated strongly with CYP2E1 activity
across species and individuals. A mathemati-
cal model was developed in which CYP2E1
activity was the only difference between
individuals or species (35). This model also
assumed that a single enzyme was responsi-
ble for oxidation, with benzene, phenol, and
hydroquinone competing for the enzymatic
reaction site. Comparing model predictions
with experimental data suggests that the
model does a fairly good job ofpredicting
data to which it has not been fit (Figure 3).
Phenol sulfation and hydroquinone
glucuronidation are the primary routes for
conjugation and detoxication of benzene
metabolites (15). The circulating levels of
the oxidized metabolites are determined by
the balance between oxidative rates and
conjugation rates. Differences in the in
vitro rates of conjugation between species
or individuals were examined in pooled
samples of rat and mouse liver and
individual samples of human liver (13).
The rate ofphenol sulfate formation varied
3-fold among human samples (range,
0.3-0.9 nmol/mg/min) (Table 2). For labo-
ratory animals, phenol sulfation was much
faster in rat cytosol (1.2 nmol/mg/min) than
in mouse cytosol (0.5 nmol/mg/min).
Hydroquinone glucuronidation varied by
almost 3-fold among human samples (range,
0.1-0.3 nmol/mg/min) (Table 2) and was
more rapid in mouse liver microsomes (0.22
nmol/mg/min) compared with rat liver
microsomes (0.08 nmol/mg/min). No cor-
relation was observed among the rates of
oxidation, sulfation, and glucuronidation
for rats, mice, or individual humans.
Given the range of activities for oxida-
tion, sulfation, and glucuronidation indi-
cated in Table 2, what phenol and
hydroquinone blood levels would occur
during benzene exposure? A physiological
compartmental model was developed to
predict steady-state blood concentrations
ofphenol and hydroquinone that might be
achieved during continuous exposure of
rodents and humans to 0.01 pM benzene
in blood (13). This blood concentration is
likely to result from exposure to benzene at
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Figure 3. Metabolism of benzene by humans, rats, and
mice, shown as a function of CYP2E1 activity. Data and
model (solid line) are adapted from Seaton et al. (35).
Table 2. Initial rates for benzene oxidation, phenol sulfation, and hydroquinone glucuronidation in five human liver
(HL) samples and single samples from mice and rats.a
Hydroquinone
Benzene oxidation, Phenol sulfation, glucuronidation,
Sample nmol/mg/min nmol/mg/min nmol/mg/min
HL 1 0.344 0.309 ND
HL2 0.926 0.581 0.117
HL6 1.433 0.867 0.281
HL7 1.499 0.919 0.167
HL 10 4.442 0.485 0.106
Mouse 1.558 0.485 0.218
Rat 0.625 1.195 0.077
ND, not determined due to insufficient sample. aResults from Seaton et al. (13).
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the current 1 ppm Occupational Safety
and Health Administration permissible
exposure limit (2).
The predicted steady-state phenol and
hydroquinone concentrations for the indi-
vidual humans, rats, and mice are depicted
in Figure 4. According to model calcula-
tions, predicted steady-state phenol concen-
trations varied 6-fold among humans and
correlated inverselywith measured microso-
mal activity ofCYP2E1. This inverse rela-
tionship is most likely due to the fact that
CYP2E1 is also responsible for phenol oxi-
dation to hydroquinone in this model.
'While the rate ofphenol formation increases
with CYP2E1 activity, the rate ofremoval
also increases with CYP2E1 activity, result-
ing in a net decrease in concentration.
Steady-state hydroquinone concentrations
varied 5-fold among humans. With respect
to laboratory animals, model simulations
predicted that during exposure to this low
benzene dose, steady-state concentrations of
phenol and hydroquinone would be higher
in mice than in rats. These predictions are
in agreement with in vivo observations
from studies with higher benzene concen-
trations (15). Predicted steady-state con-
centrations in mice were higher than in
humans, whereas values for rats fell among
the range ofpredictions for humans. These
simulations suggest that the rat may be a
good model for humans with respect to
tissue dosimetry ofbenzene metabolites.
Higher levels ofoxidized metabolites in
mice are due in part to the faster blood
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Figure 4. Predicted steady-state blood concentrations
of phenol and hydroquinone for 10 individual humans,
B6C3F1 mice, and F344 rats when the blood concentra-
tion of benzene was constant at 0.01 pM. This blood
concentration is approximately whatwould be expected
for a continuous exposure to 1 ppm benzene. The
steady-state phenol and hydroquinone concentrations
are calculated from in vitro oxidation and conjugation
activities using the physiological compartmental model
reported by Seaton et al. ( 13). Figure adapted from
Schlosser et al. (39), with permission.
flow per unit body weight in this small
species compared with humans. More ben-
zene is brought to the liver for metabolism
per unit oftime. The model predictions for
higher concentrations ofoxidized metabo-
lites in mouse blood also suggest that
development of leukemia in humans is a
function of tissue response in addition to
dosimetry. The model predicts levels ofthe
leukemogenic benzene metabolites in mice
that are higher than those predicted for
humans, and yet these levels do not give
rise to acute myelogenous leukemia in
mice. Ifthese model predictions are correct,
mouse bone marrow apparently responds to
these agents in a manner that is qualita-
tively different from that in humans.
Variability in rates ofconjugation plays
a definite role in determining steady-state
blood concentrations ofphenol and hydro-
quinone. Although the in vitro rate con-
stants for benzene oxidation vary 13-fold
among human samples, the steady-state
concentration ofphenol in blood vary only
6-fold. Moreover, steady-state concentra-
tions ofhydroquinone do not correlate with
rates ofoxidation reactions and appear to be
influenced more by competition between
phenol sulfation and phenol oxidation and
detoxication due to hydroquinone glu-
curonidation. While the effect ofthe hydro-
quinone:phenol concentration ratio in
blood on susceptibility to benzene toxicity is
not clear, a synergistic relationship between
these metabolites has been demonstrated
in vitro (7,10,36,37).
The results described above suggest a
significant interaction between phase I
(oxidation) and phase II (conjugation)
pathways in determining blood and tissue
levels ofbenzene metabolites. The quality
ofthese predictions should be tested in lab-
oratory animals in vivo before using them
for human risk assessment. Once this has
been done, a model like that described
here, taken together with the observed
ranges ofenzyme activities among humans,
can be used to predict risk to individual
humans with given enzyme activity profiles.
Subsequently, the range ofrisk to human
populations can be assessed.
Conclusions
The multiple metabolic pathways for
benzene provide opportunities for modula-
tion ofbenzene metabolism through compe-
tition between benzene and its metabolites,
competition among the various enzymes
for the substrate, and interactions of the
metabolites in producing the toxicant.
Specific examples ofthese interactions and
the net effect on the formation ofthe toxic
benzene metabolites have been discussed.
The dose-dependent metabolism
observed for benzene is most likely the
result ofcompetition between benzene and
phenol for the same oxidative enzymes.
The complex dose-response relationship
observed between benzene exposure and
metabolite formation suggests that mathe-
matical formulations of this mechanism
must be incorporated into models designed
to predict the dosimetry ofbenzene metabo-
lites. The greater fraction of the adminis-
tered dose metabolized to hydroquinone
after gavage with benzene compared with
phenol can be explained by the hetero-
geneous distribution ofphase I and phase II
enzymes in the liver. Heterogeneous enzyme
distribution may explain why benzene
exposure results in genotoxicity and car-
cinogenicity, while phenol exposure does
not, even though a common metabolite,
hydroquinone, has been implicated in the
toxicity ofbenzene.
Because phenol and hydroquinone are
components ofa normal diet and may also
arise through normal metabolic processes,
the contribution ofexogenous and endoge-
nous sources ofthese two chemicals must
be considered in estimating the total tissue
dose ofhydroquinone and the rate ofgeno-
toxic and cytotoxic damage. Incorporation
of competitive interactions between sub-
strates, heterogeneous distribution of
hepatic enzymes, and synergistic interac-
tions between metabolites into biologi-
cally based models of benzene should
result in simulations oftoxic metabolites in
the bone marrow that are more predictive
ofobserved toxicity. Ultimately, it should
be possible to use biologically based model
predictions of bone marrow dosimetry to
predict risks for humans exposed to low
concentrations of benzene, including the
combination of model predictions for
benzene metabolites derived from both
endogenous and exogenous sources.
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